Latest Commercial Milestones News

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Weebit Nano has solidified its position in the semiconductor memory sector by signing a major licensing agreement with onsemi and raising A$50 million in capital. The company is well-funded and advancing multiple commercial and technical milestones.

Mount Ridley Mines has completed a 1-for-10 capital consolidation and refreshed its board with experienced new directors, positioning itself for strategic growth amid ongoing portfolio evaluations.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Industrial Minerals Ltd reports encouraging progress in its High Purity Quartz projects, including promising testwork results and strategic marketing efforts in China, supported by a recent $2.3 million capital raise.

NH3 Clean Energy has made significant strides in its WAH2 Project, finalising critical commercial agreements and progressing technical work ahead of Front End Engineering and Design (FEED) entry scheduled for Q1 2025. The company also completed a capital raise to support these developments.

AnteoTech has marked a pivotal quarter with its first commercial Ultranode™ order shipped to Mercedes-Benz and a $4.3 million capital raise to accelerate growth in clean energy and life sciences.

BPH Global has completed its acquisition of Indonesian seaweed assets, establishing a wholly owned subsidiary and launching joint operations aimed at expanding seaweed cultivation and bio-stimulant product development across Asia.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.